Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
about
Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai ChildrenNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewDengue Fever: Causes, Complications, and Vaccine StrategiesUnderstanding the dengue viruses and progress towards their controlRational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaquesSerotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus FamilyPhase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersDengue research opportunities in the AmericasIssues related to recent dengue vaccine development.Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control.Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.Bioinformatics in new generation flavivirus vaccines.Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.Dengue in Thailand and Cambodia: an assessment of the degree of underrecognized disease burden based on reported cases.Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.National dengue surveillance in Cambodia 1980-2008: epidemiological and virological trends and the impact of vector controlDengue vaccines: state of the art.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.Dengue vaccines: recent developments, ongoing challenges and current candidates.Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysisHealth economics of dengue: a systematic literature review and expert panel's assessment.Forecasting dengue vaccine demand in disease endemic and non-endemic countries.Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areasSafety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infantsDevelopment and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccineNext-generation dengue vaccines: novel strategies currently under development.Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studySculpting humoral immunity through dengue vaccination to enhance protective immunityA phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialA dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.Domain III of the envelope protein as a dengue vaccine target.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultationA molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.
P2860
Q26314710-EC9312E8-64FF-4E5A-9944-5F6D4982C789Q26700078-CFFF8A6B-9E61-4D2D-9122-D65758B3D496Q26700082-7A9246A7-BA91-4598-B481-293F371FD75FQ27011587-585DBA01-F2C6-4103-868A-8FC6AC5A97BAQ27334248-BD4D9AEB-365E-4A98-B682-6FC4BDD11BBFQ27490960-F8498071-E871-45EA-82D2-FC35508ECFBCQ27490989-A715B7F1-6CE2-43AE-935A-E17643FB8BC7Q28656204-D274107E-5189-4CA9-876E-53FD75BBBA6CQ30395396-B73D86A3-F086-410A-8CFD-E2D38334F3DCQ33699057-0222E41D-ECC8-482C-9B9C-626623FC0ED7Q33709817-6913C53F-8F5C-478B-AE73-CA13451AA494Q33743890-8BAA7318-7026-4DEC-A816-731DE732AFE7Q33839001-E2E60953-6ACA-4FA6-ADD9-9FB9B74AB30AQ33841045-1D515E57-8FCF-4FB9-9CEB-766A2904E421Q33863578-5018EA1D-E545-4F0E-8511-0ED0F9C5B395Q33961878-083C7A27-B1D7-4C91-AD28-E69AC4034A28Q33988937-A9EC66F1-C321-4309-8B4B-F83B785AD06DQ34092769-2CBFB424-0509-4F8D-84C2-D431B4F577BEQ34109652-80B160F5-2A82-4D1F-815E-2538EE7E1A6CQ34202440-ECF3FAB8-CE00-45DC-8A04-629DB6DA5E1CQ34306877-67F267BC-2B88-48E7-B2C7-752724110834Q34367194-841132A4-867D-4864-8B37-321C707D39DAQ34423720-3046B364-3989-4023-AE02-8E81FEF9D918Q34592267-39EEC887-CE11-45E8-AA0C-BC352068B0E6Q34663963-D94FA0C5-5164-4630-A7BE-EC32C6C17C7BQ34663993-D2A66A08-997B-46AE-92D6-F12F32EDFCFFQ35131443-5BD07A2E-288F-4E91-B9E6-17C68B025906Q35206695-A1C8D63D-1A1E-4C4E-B3FD-9676AC928D93Q35491639-4138AB0C-5486-4106-AAE6-AAC17A03B8A1Q35624552-1FD0104C-78E9-4387-BF89-CA4D822E97C0Q36024479-E93E3720-1397-49F8-B56C-750EF3F005CFQ36288109-00B7D7FB-5630-4859-A614-9BA5D4CEE5E9Q36382589-87F4D353-9AE9-4108-9CD7-59EBB28EE455Q36523070-011129D0-9C6F-4916-B7DD-DA82FA1669A2Q36607295-25042553-DC9A-4B31-BB4B-C4687DDCFE05Q36849774-57D542E3-E467-42DC-93D3-11D83FBBE861Q37682895-0FEA6031-BEFA-46BE-82FD-3BF6E86CD210Q37694855-541C0F4A-DC4A-4D1D-BF88-82B9F29D3EBFQ37706823-05741064-825B-4D1C-9549-FEA7D82F4206Q37812291-3BCCB3DD-FE5A-4037-8D61-EB9CBE74307A
P2860
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@en
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@nl
type
label
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@en
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@nl
prefLabel
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@en
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@nl
P2093
P921
P356
P1433
P1476
Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.
@en
P2093
David W Vaughn
Dennis Cunningham
J Robert Putnak
Judith Perry
Kenneth H Eckels
Niranjan Kanesa-Thasan
Robert Edelman
Stephen J Thomas
Steven S Wasserman
Wellington Sun
P356
10.4161/HV.5.1.6348
P5008
P577
2009-01-27T00:00:00Z